Osteoprotegerin Is Associated With Silent Coronary Artery Disease in High-Risk but Asymptomatic Type 2 Diabetic Patients
Article Figures & Tables
Tables
- Table 1—
Characteristics of the CAD and NO-CAD groups
CAD NO-CAD P n 20 20 Sex (men/women) 15/5 15/5 1.000 Age (years) 59.8 ± 9.5 60.9 ± 9.6 0.723 Duration of diabetes (years) 12.0 ± 6.6 10.5 ± 5.9 0.444 BMI (kg/m2) 29.8 ± 4.5 29.0 ± 3.6 0.543 A1C (%) 8.9 ± 2.7 8.3 ± 2.0 0.434 Left ventricular ejection fraction 56 ± 8 61 ± 9 0.059 Total cholesterol (mg/dl) 211 ± 39 198 ± 38 0.281 LDL cholesterol (mg/dl) 131 ± 37 104 ± 41 0.033 HDL cholesterol (mg/dl) 45 ± 8 58 ± 17 0.005 Triglycerides (mg/dl) 145 (59–395) 142 (72–390) Subjects with triglycerides >150 mg/dl (%) 45.0 50.0 0.752 Nephropathy (%) 50.0 5.0 0.001 Retinopathy (%) 40.0 25.0 0.311 PAD (%) 20.0 0.0 0.035 Smokers (%) 35.0 20.0 0.288 Family history of CAD (%) 5.0 0.0 0.311 Hypertension (%) 95.0 85.0 0.282 Lp(a) (mg/dl) 13 (10–165) 21 (10–95) Subjects with Lp(a) levels >30 mg/dl (%) 30.0 40 0.507 hs-CRP (mg/l) 3.30 (0.37–28.24) 1.92 (0.06–13.40) Subjects with hs-CRP levels >median value (%) 60.0 35.0 0.113 Adiponectin (μg/ml) 7.17 (1.13–33.34) 11.55 (3.72–46.55) Subjects with adiponectin levels <median value (%) 60.0 40.0 0.206 OPG (pmol/l) 13.97 (1.31–20.04) 9.44 (0.10–25.88) Subjects with OPG levels >median value (%) 70.0 25.0 0.004 -
Data are means ± SD or median (range) unless otherwise indicated.
-